Cargando…

Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand

BACKGROUND: Māori men in New Zealand have higher mortality from prostate cancer, despite having lower incidence rates. The objective of this study was to examine patterns of screening for prostate cancer in primary care and follow-up investigations after an elevated prostate-specific antigen (PSA) r...

Descripción completa

Detalles Bibliográficos
Autores principales: Obertová, Zuzana, Scott, Nina, Brown, Charis, Hodgson, Fraser, Stewart, Alistair, Holmes, Michael, Lawrenson, Ross
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254388/
https://www.ncbi.nlm.nih.gov/pubmed/25154420
http://dx.doi.org/10.1186/1471-2296-15-145
_version_ 1782347334199279616
author Obertová, Zuzana
Scott, Nina
Brown, Charis
Hodgson, Fraser
Stewart, Alistair
Holmes, Michael
Lawrenson, Ross
author_facet Obertová, Zuzana
Scott, Nina
Brown, Charis
Hodgson, Fraser
Stewart, Alistair
Holmes, Michael
Lawrenson, Ross
author_sort Obertová, Zuzana
collection PubMed
description BACKGROUND: Māori men in New Zealand have higher mortality from prostate cancer, despite having lower incidence rates. The objective of this study was to examine patterns of screening for prostate cancer in primary care and follow-up investigations after an elevated prostate-specific antigen (PSA) result in Māori and non-Māori men in order to help explain the observed differences in incidence and mortality. METHODS: Men aged 40+ years were identified from 31 general practices across the Midland Cancer Network region. Computerised practice records were cross-referenced with laboratory data to determine the number and value of PSA tests undertaken between January 2007 and December 2010. Screening rates were calculated for the year 2010 by age, ethnicity, and practice. For men with an elevated PSA result information on specialist referrals and biopsy was extracted from practice records. Practice characteristics were assessed with respect to screening rates for Māori and non-Māori men. RESULTS: The final study population included 34,960 men aged 40+ years; 14% were Māori. Māori men were less likely to be screened in 2010 compared with non-Māori men (Mantel Haenszel (M-H) age-adjusted risk ratio (RR), 0.52 [95% CI, 0.48, 0.56]). When screened, Māori men were more than twice as likely to have an elevated PSA result compared with non-Māori men (M-H age-adjusted RR, 2.16 [95% CI, 1.42, 3.31]). There were no significant differences between Māori and non-Māori men in the rate of follow-up investigations and cancer detection. Māori provider practices showed equal screening rates for Māori and non-Māori men, but they were also the practices with the lowest overall screening rates. CONCLUSIONS: Māori men were half as likely to be screened compared to non-Māori men. This probably explains the lower reported incidence of prostate cancer for Māori men. Practice characteristics had a major influence on screening rates. Large variation in screening behaviour among practices and differences in follow-up investigations for men with an elevated PSA result seems to reflect the uncertainty among GPs regarding PSA screening and management.
format Online
Article
Text
id pubmed-4254388
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42543882014-12-04 Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand Obertová, Zuzana Scott, Nina Brown, Charis Hodgson, Fraser Stewart, Alistair Holmes, Michael Lawrenson, Ross BMC Fam Pract Research Article BACKGROUND: Māori men in New Zealand have higher mortality from prostate cancer, despite having lower incidence rates. The objective of this study was to examine patterns of screening for prostate cancer in primary care and follow-up investigations after an elevated prostate-specific antigen (PSA) result in Māori and non-Māori men in order to help explain the observed differences in incidence and mortality. METHODS: Men aged 40+ years were identified from 31 general practices across the Midland Cancer Network region. Computerised practice records were cross-referenced with laboratory data to determine the number and value of PSA tests undertaken between January 2007 and December 2010. Screening rates were calculated for the year 2010 by age, ethnicity, and practice. For men with an elevated PSA result information on specialist referrals and biopsy was extracted from practice records. Practice characteristics were assessed with respect to screening rates for Māori and non-Māori men. RESULTS: The final study population included 34,960 men aged 40+ years; 14% were Māori. Māori men were less likely to be screened in 2010 compared with non-Māori men (Mantel Haenszel (M-H) age-adjusted risk ratio (RR), 0.52 [95% CI, 0.48, 0.56]). When screened, Māori men were more than twice as likely to have an elevated PSA result compared with non-Māori men (M-H age-adjusted RR, 2.16 [95% CI, 1.42, 3.31]). There were no significant differences between Māori and non-Māori men in the rate of follow-up investigations and cancer detection. Māori provider practices showed equal screening rates for Māori and non-Māori men, but they were also the practices with the lowest overall screening rates. CONCLUSIONS: Māori men were half as likely to be screened compared to non-Māori men. This probably explains the lower reported incidence of prostate cancer for Māori men. Practice characteristics had a major influence on screening rates. Large variation in screening behaviour among practices and differences in follow-up investigations for men with an elevated PSA result seems to reflect the uncertainty among GPs regarding PSA screening and management. BioMed Central 2014-08-26 /pmc/articles/PMC4254388/ /pubmed/25154420 http://dx.doi.org/10.1186/1471-2296-15-145 Text en © Obertová et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Obertová, Zuzana
Scott, Nina
Brown, Charis
Hodgson, Fraser
Stewart, Alistair
Holmes, Michael
Lawrenson, Ross
Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand
title Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand
title_full Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand
title_fullStr Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand
title_full_unstemmed Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand
title_short Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand
title_sort prostate-specific antigen (psa) screening and follow-up investigations in māori and non-māori men in new zealand
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254388/
https://www.ncbi.nlm.nih.gov/pubmed/25154420
http://dx.doi.org/10.1186/1471-2296-15-145
work_keys_str_mv AT obertovazuzana prostatespecificantigenpsascreeningandfollowupinvestigationsinmaoriandnonmaorimeninnewzealand
AT scottnina prostatespecificantigenpsascreeningandfollowupinvestigationsinmaoriandnonmaorimeninnewzealand
AT browncharis prostatespecificantigenpsascreeningandfollowupinvestigationsinmaoriandnonmaorimeninnewzealand
AT hodgsonfraser prostatespecificantigenpsascreeningandfollowupinvestigationsinmaoriandnonmaorimeninnewzealand
AT stewartalistair prostatespecificantigenpsascreeningandfollowupinvestigationsinmaoriandnonmaorimeninnewzealand
AT holmesmichael prostatespecificantigenpsascreeningandfollowupinvestigationsinmaoriandnonmaorimeninnewzealand
AT lawrensonross prostatespecificantigenpsascreeningandfollowupinvestigationsinmaoriandnonmaorimeninnewzealand